Anne Filppula

Publications

Research output per year 2010 2013 2014 2016 2018 2019 2021 2023 2024 2024

• 26 Article
• 2 Review Article or Literature Review

Research output per year

Research output per year

Search results

• 2024

  Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes – detailed studies on CYP3A inhibitors

  Kahma, H., Paludetto, M-N., Neuvonen, M., Kurkela, M., Filppula, A. M., Niemi, M. & Backman, J. T., Feb 2024, In: European Journal of Pharmaceutical Sciences.

  Research output: Contribution to journal › Article › Scientific › peer-review

• Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity

  Kiiski, J. I., Neuvonen, M., Kurkela, M., Hirvensalo, P., Hämäläinen, K., Tarkiainen, E. K., Sistonen, J., Korhonen, M., Khan, S., Orpana, A., Filppula, A. M., Lehtonen, M. & Niemi, M., 1 Feb 2024, In: Human genomics. 18, 1, 16 p., 11.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File

  • CYP2D6 100%
  • Solanidine 100%
  • Blood Plasma 50%
  • Genotyping 17%
  • Drug-Drug Interaction 16%
  4 Downloads (Pure)

• Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

  Lehtisalo, M., Tarkiainen, E. K., Neuvonen, M., Holmberg, M., Kiiski, J. I., Lapatto‐Reiniluoto, O., Filppula, A. M., Kurkela, M., Backman, J. T. & Niemi, M., Jan 2024, In: Clinical Pharmacology & Therapeutics. 115, 1, p. 71-79 9 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File

  • ABCG2 100%
  • Ticagrelor 100%
  • Glycochenodeoxycholic Acid 15%
  • Glycodeoxycholic Acid 15%
  • Placebo 15%
  9 Downloads (Pure)
• 2023

  Fabricating biomimetic materials with ice‐templating for biomedical applications

  Lin, X., Fan, L., Wang, L., Filppula, A. M., Yu, Y. & Zhang, H., Aug 2023, In: Smart Medicine. 2, 3, 14 p., e20230017.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File
  9 Downloads (Pure)

• Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants

  Lönnberg, K. I., Tornio, A., Hirvensalo, P., Keskitalo, J., Mustaniemi, A-L., Kiiski, J. I., Filppula, A. M. & Niemi, M., Sept 2023, In: Pharmacogenetics and Genomics. 33, 7, p. 153-160 8 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File

  • Pharmacogenetics 100%
  • ABCG2 100%
  • SLCO1B1 100%
  • Creatine Kinase 11%
  • Allele 10%
  2 Citations (Scopus)

  20 Downloads (Pure)

• Rhabdomyolysis during concomitant ticagrelor and rosuvastatin - a breast cancer resistance protein -mediated drug interaction?

  Lehtisalo, M., Kiander, W., Filppula, A. M., Deng, F., Kidron, H., Korhonen, M., Sinkko, J., Koivula, K. & Niemi, M., Jul 2023, In: British Journal of Clinical Pharmacology. 89, 7, p. 2309-2315 7 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File

  • Rosuvastatin 100%
  • Ticagrelor 80%
  • Rhabdomyolysis 40%
  • ABCG2 30%
  • Drug Interaction 20%
  5 Citations (Scopus)

  57 Downloads (Pure)
• 2022

  Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A in vitro

  Paludetto, M-N., Kurkela, M., Kahma, H., Backman, J. T., Niemi, M. & Filppula, A. M., 29 Nov 2022, (E-pub ahead of print) In: Drug Metabolism and Disposition.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File

  • Hydroxychloroquine 100%
  • Cytochrome P450 2D6 66%
  • CYP2D6 55%
  • CYP3A4 44%
  • Cytochrome P450 3A4 44%
  11 Citations (Scopus)

  38 Downloads (Pure)
• 2021

  An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes – application to establishing CYP2C8 inhibitor selectivity

  Kahma, H., Aurinsalo, L., Neuvonen, M., Katajamäki, J., Paludetto, M-N., Viinamäki, J., Launiainen, T., Filppula, A. M., Tornio, A., Niemi, M. & Backman, J. T., Jul 2021, In: European Journal of Pharmaceutical Sciences. 162, 105810.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  File
  10 Citations (Scopus)

  80 Downloads (Pure)

• Comparative Hepatic and Intestinal Efflux Transport of Statins ^S

  Deng, F., Tuomi, S-K., Neuvonen, M., Hirvensalo, P., Kulju, S., Wenzel, C., Oswald, S., Filppula, A. M. & Niemi, M., 1 Sept 2021, In: Drug Metabolism and Disposition. 49, 9, p. 750-759

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  • Statin 100%
  • Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 88%
  • Atorvastatin 77%
  • Effusion 77%
  • Fluindostatin 55%
  33 Citations (Scopus)

• Comparative hepatic and intestinal metabolism and pharmacodynamics of statins

  Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F., Viinamäki, J., Kurkela, M., Neuvonen, M. & Niemi, M., 1 Aug 2021, In: Drug Metabolism and Disposition. 49, 8, p. 658-667

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access

  • Lactone 100%
  • Acid 66%
  • Simvastatin 50%
  • Atorvastatin 50%
  • Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 50%
  20 Citations (Scopus)
• 2019

  Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation

  Tornio, A., helsinki, U., Niemi, M. & Backman, J. T., 2019, In: Clinical Pharmacology and Therapeutics.

  Research output: Contribution to journal › Article › Scientific › peer-review
  104 Citations (Scopus)

• Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8

  Kahma, H., Filppula, A. M., Launiainen, T., Viinamäki, J., Neuvonen, M., Evangelista, E. A., Totah, R. A. & Backman, J. T., 1 Apr 2019, In: Drug Metabolism and Disposition.

  Research output: Contribution to journal › Article › Scientific › peer-review
  7 Citations (Scopus)

• Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

  Filppula, A. M., Parvizi, R., Mateus, A., Baranczewski, P. & Artursson, P., Dec 2019, In: Scientific Reports.

  Research output: Contribution to journal › Article › Scientific › peer-review

  Open Access
  13 Citations (Scopus)
• 2018

  Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans

  Itkonen, M. K., Tornio, A., Filppula, A. M., Neuvonen, M., Neuvonen, P. J., Niemi, M. & Backman, J. T., 2018, In: Clinical Pharmacology and Therapeutics.

  Research output: Contribution to journal › Article › Scientific › peer-review
  13 Citations (Scopus)

• Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions 

  Kahma, H., Filppula, A. M., Neuvonen, M., Tarkiainen, E. K., Tornio, A., Holmberg, M. T., Itkonen, M. K., Finel, M., Neuvonen, P. J., Niemi, M. & Backman, J. T., Feb 2018, In: Drug Metabolism and Disposition. 46, 2, p. 141-150 10 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  • Glucuronidation 100%
  • UGT2B7 100%
  • Glucuronosyltransferase 15%
  • Reduced Nicotinamide Adenine Dinucleotide Phosphate 7%
  • Antiplatelet Drug 7%

• In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug–Drug Interactions

  Filppula, A. M., Mustonen, T. M. & Backman, J. T., 2018, In: Basic and Clinical Pharmacology and Toxicology.

  Research output: Contribution to journal › Article › Scientific › peer-review
  13 Citations (Scopus)
• 2016

  Role of Cytochrome P450 2C8 in drug metabolism and interactions

  Backman, J. T., Filppula, A. M., Niemi, M. & Neuvonen, P. J., 2016, In: Pharmacological Reviews.

  Research output: Contribution to journal › Article › Scientific › peer-review
  167 Citations (Scopus)

• Validation and development of MTH1 inhibitors for treatment of cancer

  Berglund, U. W., Sanjiv, K., Gad, H., Kalderen, C., Koolmeister, T., Pham, T., Gokturk, C., Jafari, R., Maddalo, G., Seashore-Ludlow, B., Chernobrovkin, A., Manoilov, A., Pateras, I. S., Rasti, A., Jemth, A. S., Almlof, I., Loseva, O., Visnes, T., Einarsdottir, B. O., Gaugaz, F. Z., & 25 othersSaleh, A., Platzack, B., Wallner, O. A., Vallin, K. S. A., Wakchaure, P., Borhade, S., Herr, P., Kallberg, Y., Baranczewski, P., Homan, E. J., Wiita, E., Nagpal, V., Meijer, T., Schipper, N., Rudd, S. G., Brautigam, L., Lindqvist, A., Filppula, A., Lee, T. C., Artursson, P., Gorgoulis, V. G., Lehtio, J., Zubarev, R. A., Scobie, M. & Helleday, T., 2016, In: Annals of Oncology.

  Research output: Contribution to journal › Article › Scientific › peer-review
  104 Citations (Scopus)
• 2015

  Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma.

  Bergmann, TK., Filppula, AM., Launiainen, T., Nielsen, F., Backman, J. & Brosen, K., Oct 2015, In: British Journal of Clinical Pharmacology.

  Research output: Contribution to journal › Article › Scientific › peer-review
  18 Citations (Scopus)
• 2014

  Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.

  Tornio, A., Filppula, AM., Kailari, O., Neuvonen, M., Nyrönen, TH., Tapaninen, T., Neuvonen, PJ., Niemi, M. & Backman, JT., Oct 2014, In: Clinical Pharmacology and Therapeutics.

  Research output: Contribution to journal › Article › Scientific › peer-review
  116 Citations (Scopus)

• In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.

  Filppula, AM., Neuvonen, PJ. & Backman, JT., Jul 2014, In: Drug Metabolism and Disposition.

  Research output: Contribution to journal › Article › Scientific › peer-review
  52 Citations (Scopus)
• 2013

  Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response: Drug Metabolism and Disposition

  Filppula, A., 2013, In: Drug Metabolism and Disposition.

  Research output: Contribution to journal › Article › Scientific › peer-review
  58 Citations (Scopus)

• Gemfibrozil Impairs lmatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

  Filppula, A. M., Tornio, A., Niemi, M., Neuvonen, P. J. & Backman, J. T., 2013, In: Clinical Pharmacology & Therapeutics.

  Research output: Contribution to journal › Article › Scientific › peer-review
  28 Citations (Scopus)
• 2012

  Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates: British Journal of Pharmacology

  Filppula, A., 2012, In: British Journal of Pharmacology.

  Research output: Contribution to journal › Article › Scientific › peer-review
  81 Citations (Scopus)
• 2011

  Reevaluation of the microsomal metabolism of montelukast: Major contribution by CYP2C8 at clinically relevant concentrations

  Filppula, A. M., Laitila, J., Neuvonen, P. J. & Backman, J. T., May 2011, In: Drug Metabolism and Disposition. 39, 5, p. 904-911 8 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  • Montelukast 100%
  • CYP2C8 57%
  • Cytochrome P450 35%
  • CYP2C9 28%
  • CYP3A4 28%
  45 Citations (Scopus)
• 2010

  Gemfibrozil markedly increases the plasma concentrations of montelukast: A previously unrecognized role for CYP2c8 in the metabolism of montelukast

  Karonen, T., Filppula, A., Laitila, J., Niemi, M., Neuvonen, P. J. & Backman, J. T., Aug 2010, In: Clinical Pharmacology and Therapeutics. 88, 2, p. 223-230 8 p.

  Research output: Contribution to journal › Article › Scientific › peer-review

  • Montelukast 100%
  • Gemfibrozil 70%
  • CYP2C8 20%
  • Elimination 20%
  • Pharmacokinetics 10%
  55 Citations (Scopus)